Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M60,237Revenue $M10,936Net Margin (%)33.8Altman Z-Score6.0
Enterprise Value $M63,193EPS $16.3Operating Margin %47.1Piotroski F-Score5
P/E(ttm)16.9Beneish M-Score-3.0Pre-tax Margin (%)45.6Higher ROA y-yN
Price/Book5.810-y EBITDA Growth Rate %26.1Quick Ratio2.3Cash flow > EarningsY
Price/Sales5.85-y EBITDA Growth Rate %30.7Current Ratio2.6Lower Leverage y-yN
Price/Free Cash Flow19.3y-y EBITDA Growth Rate %17.3ROA % (ttm)19.9Higher Current Ratio y-yN
Dividend Yield %--PEG0.6ROE % (ttm)33.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M219ROIC % (ttm)33.5Gross Margin Increase y-yY

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBKen Fisher 2016-03-31 Reduce-0.01%$245.11 - $306.35
($264.69)
$ 274.994%Reduce -18.17%90,405
BIIBJoel Greenblatt 2015-12-31 Add0.25%$256.04 - $309.67
($287.66)
$ 274.99-4%Add 798.80%84,577
BIIBFirst Eagle Investment 2015-12-31 Buy 0.15%$256.04 - $309.67
($287.66)
$ 274.99-4%New holding193,885
BIIBVanguard Health Care Fund 2015-12-31 Add0.09%$256.04 - $309.67
($287.66)
$ 274.99-4%Add 3.91%3,810,023
BIIBJohn Paulson 2015-12-31 Buy 0.07%$256.04 - $309.67
($287.66)
$ 274.99-4%New holding36,200
BIIBMario Gabelli 2015-12-31 Add$256.04 - $309.67
($287.66)
$ 274.99-4%Add 0.17%4,805
BIIBKen Fisher 2015-12-31 Reduce$256.04 - $309.67
($287.35)
$ 274.99-4%Reduce -1.75%110,475
BIIBRon Baron 2015-12-31 Reduce$256.04 - $309.67
($287.66)
$ 274.99-4%Reduce -13.32%10,240
BIIBVanguard Health Care Fund 2015-09-30 Add1.19%$272.28 - $409.5
($330.23)
$ 274.99-17%Add 105.96%3,666,723
BIIBJoel Greenblatt 2015-09-30 Buy 0.03%$272.28 - $409.5
($330.23)
$ 274.99-17%New holding9,410
BIIBKen Fisher 2015-09-30 Add0.02%$272.28 - $409.5
($330.23)
$ 274.99-17%Add 38.94%112,448
BIIBRon Baron 2015-09-30 Add$272.28 - $409.5
($330.23)
$ 274.99-17%Add 29.20%11,814
BIIBVanguard Health Care Fund 2015-06-30 Add1.17%$373.93 - $430.96
($401.66)
$ 274.99-32%Add 425.02%1,780,330
BIIBMario Gabelli 2015-06-30 Reduce$373.93 - $430.96
($401.66)
$ 274.99-32%Reduce -2.74%4,797
BIIBKen Fisher 2015-06-30 Reduce$373.93 - $430.96
($401.66)
$ 274.99-32%Reduce -0.16%80,932
BIIBVanguard Health Care Fund 2015-03-31 Buy 0.31%$334.65 - $475.98
($394.14)
$ 274.99-30%New holding339,100
BIIBJoel Greenblatt 2015-03-31 Sold Out -0.014%$334.65 - $475.98
($394.14)
$ 274.99-30%Sold Out0
BIIBMario Gabelli 2015-03-31 Reduce$334.65 - $475.98
($394.14)
$ 274.99-30%Reduce -0.06%4,932
BIIBKen Fisher 2015-03-31 Add$334.65 - $475.98
($394.14)
$ 274.99-30%Add 2.28%81,058
BIIBKen Heebner 2014-12-31 Sold Out -0.75%$299.1 - $360.67
($323.29)
$ 274.99-15%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Koppel AdamEVP, Strategy and Bus. Dev. 2016-04-06Sell102$275-0view
SCANGOS GEORGE ACEO 2016-04-06Sell157$280-1.79view
SCANGOS GEORGE ACEO 2016-04-01Sell487$258.836.24view
SCANGOS GEORGE ACEO 2016-03-01Sell487$261.375.21view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2016-02-25Sell183$261.95view
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff 2016-02-25Sell84$261.95view
SCANGOS GEORGE ACEO 2016-02-17Sell487$256.167.35view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2016-02-17Sell722$256.167.35view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2016-02-09Sell852$246.5411.54view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2015-12-04Sell441$277-0.73view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about BIIB:

Articles On GuruFocus.com
10 Years of Strong Returns: Priceline, Biogen Apr 26 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Undervalued Stocks With Wide Margin of Safety Apr 14 2016 
John Buckingham Trades in ETFs in 4th Quarter Mar 15 2016 
Widely Undervalued Stocks Trading Below Peter Lynch Value Feb 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Feb 10 2016 
Jean Hynes Finds Her Pot of Gold Jan 07 2016 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Biogen Among Murray Stahl's Holdings With Growing Earnings Nov 11 2015 

More From Other Websites
[$$] The Barron's 500: AmerisourceBergen Ranks No. 1 Apr 29 2016
Apple Drives Selloff on April's Last Trading Day Apr 29 2016
Stocks Sell Off in Final Trading Day of April Apr 29 2016
What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead Apr 29 2016
ADAM KOPPEL, EXECUTIVE VICE PRESIDENT, STRATEGY AND BUSINESS DEVELOPMENT, TO RETURN TO BAIN CAPITAL Apr 29 2016
BIOGEN INC. Files SEC form 8-K, Other Events Apr 29 2016
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment... Apr 29 2016
7:40 am Biogen and AbbVie (ABBV) announce the EMA adopted a... Apr 29 2016
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment... Apr 29 2016
Biogen, AbbVie multiple sclerosis drug wins EU green light Apr 29 2016
ETF’s with exposure to Biogen, Inc. : April 28, 2016 Apr 28 2016
Biotech Boom May Continue Through Earnings Season Apr 28 2016
Tysabri Reports Strong Patient Growth in 1Q16 Apr 28 2016
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Apr 28 2016
Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Apr 27 2016
BIOGEN INC. Financials Apr 27 2016
Why Biogen Is Poaching This Pfizer Exec to Head Up Its R&D Shop Apr 27 2016
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development Apr 27 2016
Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 27 2016
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development Apr 27 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)